Valeant (VRX) to Buy Salix Pharmaceuticals (SLXP) for $10.1Billion: Report

Valeant Pharmaceuticals Int’l Inc. (VRX) has agreed to buy drugmaker Salix Pharmaceuticals (SLXP) for $158 per share, CNBC reported on Saturday. The all-cash deal, which values Salix at about $10.1 billion, would be the largest ever for Valeant and could be announced as soon as Sunday, according to the publication. Salix shares rose $7.11 to […] View the full post at: Valeant (VRX) to Buy Salix Pharmaceuticals (SLXP) for $10.1Billion: Report Related posts: First Piedmont Bank of Georgia Fails; Tally Rises to 54 for ’09 American Southern Bank Goes Bust A Drug Stock With Potential For Solid Gain